



Countervail Corporation



Contact: Bill Basinger, CEO **Location:** Charlotte, NC **Email:** bbasinger@countervailcorp.com **Tel:** 704-688-5520 **Website:** <http://www.countervailcorp.com>



Company Profile

Industry Sector: Pharmaceutical

Company Overview: Countervail was formed in 2007 to commercialize a novel drug discovery found to be effective in preventing poisoning from chemical warfare agents and a large class of pesticides. In 2014, two additional complimentary novel drug technologies were acquired and an improved companion diagnostic test has been designed. All technologies are patented or patent pending.

Target Market(s): Strategic National Stockpile, First Responder Sites, US/Allied Military, Metropolitan Hospitals and clinics



Key Value Drivers

Technology*: Lead drug compound, galantamine, protects against organophosphate (nerve agent and pesticide) toxicity by preventing the inactivation of a critical neural system enzyme, AChE.

Competitive Advantage:

- Significantly improved survival and neuroprotection
- Crosses the blood-brain-barrier to protect the CNS
- Oral or parenteral dosing
- Repurposed drug –safe use in humans for decades

Plan & Strategy: Take advantage of advanced development status of a repurposed drug with initial focus on anti-nerve agent indications due to federal agency interest followed by improved companion diagnostic and anti-OP pesticide indications. Supplement federal funding with strategic investment partner.



Management

Leadership: G. William Basinger, Jr.: Founder/CEO/President - >30 Yrs in pharma and diagnostic industries with executive management in business dev., sales and marketing. BS & MS degrees. Richard Gammans, PhD: Director Drug Development - >30 Yrs of drug experience. Successfully developed 7 new molecular entities and obtained 50 national marketing authorizations with 7 approved NDAs.

Scientific Advisory Board: Edson X. Albuquerque, MD, PhD – UMB, School of Medicine. Internationally recognized for his electrophysiological research on neurotransmitter receptors.

Palmer Taylor, PhD – UCSD, Scaggs School of Pharm.- Cloned the first acetylcholinesterase (AChE) gene and is an expert in AChE molecular structure.



Product Development Pipeline

Product	2017	2018
Galantamine for Pre-Exposure Prophylaxis against Nerve Agents for Improved Survival (CAP-SBIR)		
OP Exposure Diagnostic Test		

- Galantamine for Post Exposure Treatment– Nerve Agents for Improved Survival
- Galantamine for Post Sub-Lethal Nerve Agent Exposure Treatment for Neuroprotection
- Galantamine for Post Acute OP Pesticide Exposure Treatment for Improved Survival/Neuroprotection
- Galantamine for Pre-Exposure Prophylaxis / Chronic Exposure to Pesticides for Neuroprotection
- AChE Oxime [Nerve Agent/OP Pesticide]



Small Business Innovation Research (SBIR)
Small Business Technology Transfer (STTR)

National Institutes of Health
Commercialization Assistance Program (NIH CAP)

